[Evolution of severe mitral regurgitation after optimization of pharmacological therapy in non-ischemic dilated cardiomyopathy].
In dilated cardiomyopathy, severe functional mitral regurgitation (MR) is associated with a poor prognosis. In 112 consecutive clinically stable patients with non-ischemic dilated cardiomyopathy, echocardiography identified 15 (14%) patients who had severe MR (age, 53+/-12 years; 80% male; left ventricular ejection fraction, 26 +/- 8%). Existing medical treatment with ACE inhibitors and beta-blockers was increased up to the maximum tolerated doses. At 6 months, MR decreased by at least one grade in 13 (87%) patients (P =.001), as did the effective regurgitant orifice area (from 0.41 [0.05] mm2 to 0.20 [0.15] mm2; P.
Pascual Figal
Domingo A
DA
Servicio de Cardiología, Hospital Universitario Virgen de la Arrixaca, Murcia, España. dapascual@servicam.com
de la Morena Valenzuela
Gonzalo
G
González Carrillo
Josefa
J
Ansaldo Ruiz
Pilar
P
Ruipérez Abizanda
Juan A
JA
Valdés Chavarri
Mariano
M
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D002311:Cardiomyopathy, Dilated / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D003627:Data Interpretation, Statistical; D004452:Echocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000000981:diagnostic imaging / Q000209:etiology* / Q000503:physiopathology; D013318:Stroke Volume; D013997:Time Factors; D016896:Treatment Outcome; D016277:Ventricular Function, Left
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors